Sperm associated antigen 9 (SPAG9) (SPAG9)

Sperm associated antigen 9 (SPAG9) is a scaffold protein belonging to the JNK-interacting protein (JIP) family, primarily involved in the regulation of the c-Jun N-terminal kinase (JNK) signaling pathway (UniProt: Q5T210). It is characterized as a cancer-testis antigen (CTA), meaning its expression is typically restricted to the immune-privileged testis but becomes highly expressed in various human cancers, such as breast, cervical, and lung carcinomas (PubMed: 21533181). In malignant cells, SPAG9 promotes tumor growth, migration, and invasion, making it a significant driver of oncogenesis (PubMed: 25600155). Because of its restricted expression pattern and vital role in cancer progression, it serves as an ideal target for immunotherapy. Therapeutic strategies, such as dendritic cell-based vaccines or T-cell therapies, aim to elicit a robust immune response involving antigen-specific T cells and natural killer (NK) cells to selectively destroy SPAG9-positive tumor cells (PubMed: 17460773). This approach leverages the high immunogenicity of SPAG9 to induce both cellular and humoral immune responses against the tumor. Clinical studies have explored SPAG9-based vaccines as a means to provide a targeted, low-toxicity treatment option for patients with advanced malignancies (PubMed: 25600155). Overall, SPAG9 represents a promising biomarker and therapeutic target in the field of precision oncology.

Other names

JNK-interacting protein 4JIP-4Cancer/testis antigen 76CT76HLC-6PHETITSperm-associated antigen 9

Induction of antigen-specific cytotoxic T lymphocyte (CTL) response and natural killer (NK) cell-mediated lysis against tumor cells expressing the SPAG9 antigen.